- Q4 2023 CureVac NV Earnings Call TranscriptApr 24, 2024€2.27 (-4.70%)Earnings
- Q3 2023 CureVac NV Earnings Call TranscriptNov 14, 2023€5.35 (+6.79%)Earnings
- CureVac NV at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q4 2022 CureVac NV Earnings Call TranscriptApr 25, 2023€6.95 (-5.18%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptMar 28, 2023
- CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs TranscriptJan 06, 2023
- Q3 2022 CureVac NV Earnings Call TranscriptNov 16, 2022€7.89 (+2.04%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptJun 22, 2022
- CureVac NV at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- CureVac NV at Jefferies Healthcare Conference TranscriptJun 09, 2022
- CureVac NV at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q4 2021 CureVac NV Earnings Call TranscriptApr 28, 2022€15.2 (-1.05%)Earnings
- Q3 2021 CureVac NV Earnings Call TranscriptNov 19, 2021€36.83 (+4.54%)Earnings
- CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call TranscriptOct 12, 2021
- CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call TranscriptJul 01, 2021
- CureVac NV Updates On Clinical Trial - Corporate Call TranscriptJun 17, 2021
- Q4 2020 CureVac NV Earnings Call TranscriptApr 15, 2021€89 (+3.91%)Earnings
- CureVac N.V. - Special Call TranscriptFeb 05, 2021
Q3 2022 CureVac NV Earnings Call Transcript
Greetings, and welcome to CureVac Third Quarter and First 9 Months 2022 Financial Results and Business Update. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Sarah Fakih, Vice President, Corporate Communications and Investor Relations. Thank you. You may begin.
Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President of Corporate Communications and Investor Relations at CureVac.
Please let me introduce today's speakers. On the call with me from CureVac are Franz-Werner Haas, the Chief Executive Officer; Ulrike Gnad-Vogt, our Interim Chief Development Officer; Ronald Plasterk, our Senior Vice President, Science and Innovation; and Pierre Kemula, Chief Financial Officer of CureVac.
Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our website.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)